Does ENZALUTAMIDE Cause Prostatic specific antigen increased? 3,731 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 3,731 reports of Prostatic specific antigen increased have been filed in association with ENZALUTAMIDE (Xtandi). This represents 7.6% of all adverse event reports for ENZALUTAMIDE.
3,731
Reports of Prostatic specific antigen increased with ENZALUTAMIDE
7.6%
of all ENZALUTAMIDE reports
321
Deaths
463
Hospitalizations
How Dangerous Is Prostatic specific antigen increased From ENZALUTAMIDE?
Of the 3,731 reports, 321 (8.6%) resulted in death, 463 (12.4%) required hospitalization, and 22 (0.6%) were considered life-threatening.
Is Prostatic specific antigen increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 3,731 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
Diarrhoea (2,470)
What Other Drugs Cause Prostatic specific antigen increased?
LEUPROLIDE (2,432)
ABIRATERONE (1,581)
RADIUM RA-223 DICHLORIDE (449)
RELUGOLIX (335)
BICALUTAMIDE (322)
DOCETAXEL (282)
APALUTAMIDE (251)
DENOSUMAB (220)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)
OLAPARIB (176)
Which ENZALUTAMIDE Alternatives Have Lower Prostatic specific antigen increased Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE